A pill called ensitrelvir is the first drug shown to effectively reduce infection after exposure to SARS-CoV-2.

Results suggest potential effectiveness in settings such as nursing homes ...

We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...

Immune-priming events such as COVID-19 and influenza vaccinations may have cross-protective effects on the incidence of other viral ARIs.

The Global Virus Network (GVN) is closely monitoring the emergence of a newly identified SARS-CoV-2 variant, NB.1.8.1, a sublineage of the Omicron family. This variant was first identified in January ...